|
Cetuximab is a monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with antitumor activity. In Vitro: Cetuximab (0, 10, 30 and 100 ug/mL) in combination with PBR extract (100, 500 ug/mL) significantly reduces the viability of SW480 colon cancer cells. Cells treated with PBR extract or Cetuximab, are a few PI-stained dead cells. In contrast, the combined treatment of Cetuximab and PBR exhibits relatively fewer cells, and most of them are red-stained dead cells. The combination of PBR extract and Cetuximab induces apoptotic cells, and reduces KRAS and p-p42/44 MAPK levels[1]. In Vivo: Cetuximab (10 mg/kg in PBS, i.p.) with PBR extract suppresses KRAS-mutated colorectal tumor growth in vivo[1]. Cetuximab (1 mg/injection) has effect on the tumour volume but the effect is more pronounced on UT-SCC-14 xenografts. In UT-SCC-14 xenografts, Cetuximab treatment significantly reduces the expression of EGFR, pEGFR and Ki67. The MCT1 and GLUT1 expression is significantly decreased in the Cetuximab-treated groups of both cell lines but differences are more pronounced in UT-SCC-14 xenografts[2].
|